Endophthalmitis caused by serratia marcescens: Clinical features, antibiotic susceptibilities, and treatment outcomes

Retina

Volumn 35, Issue 6, 2015, Pages 1095-1100

  Sridhar, Jayanth ^a   Kuriyan, Ajay E ^a   Flynn, Harry W ^a   Smiddy, William E ^a   Venincasa, Vincent D ^a   Miller, Darlene ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

endophthalmitis; serratia

Indexed keywords

AMIKACIN; CEFTAZIDIME; DEXAMETHASONE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PREDNISOLONE ACETATE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE STUDY; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL FEATURE; ENDOPHTHALMITIS; EYE PAIN; EYE SURGERY; GLAUCOMA DRAINAGE IMPLANT; HAND MOVEMENT; HUMAN; HYPOPYON; INTRAOCULAR PRESSURE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENETRATING KERATOPLASTY; POSTOPERATIVE INFECTION; SCLERAL BUCKLE; SERRATIA INFECTION; SERRATIA MARCESCENS; TRABECULECTOMY; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY; DRUG COMBINATION; DRUG EFFECTS; EYE INFECTIONS, BACTERIAL; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; SERRATIA INFECTIONS;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SERRATIA INFECTIONS; SERRATIA MARCESCENS; VISUAL ACUITY; VITREOUS BODY;

EID: 84930457449     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000509     Document Type: Article

References (20)

1. Hejazi A, Falkiner FR. Serratia marcescens. J Med Microbiol 1997;46:903-912.
2. Samonis G, Vouloumanou EK, Christofaki M, et al. Serratia infection in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis 2011;30:653-660.
3. Radda TM. Metastatic Serratia marcescens endophthalmitis. Ophthalmologica 1982;185:65-68.
4. al Hazzaa SA, Tabbara KF, Gammon JA. Pink hypopyon: a sign of Serratia marcescens endophthamitis. Br J Ophthalmol 1992;76:764-765.
5. Cohen SM, Flynn HW Jr, Miller D. Endophthalmitis caused by Serratia marcescens. Ophthalmic Surg Lasers 1997;28:195-200.
6. Marinella MA, Warwar R. Endogenous endophthalmitis due to Serratia marcescens. South Med J 1998;91:388-391.
7. Equi RA, Green WR. Endogenous Serratia endophthalmitis with dark hypopyon: case report and review. Surv Ophthalmol 2001;46:259-268.
8. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995;113:1479-1496.
9. Gammon JA, Schwab I, Joseph P. Gentamicin-resistant Serratia marcescens endophthalmitis. Arch Ophthalmol 1980;98: 1221-1223.
10. Shaarawy A, Grand MG, Meredith TA, Ibanez HE. Persistent endophthalmitis after intravitreal therapy. Ophthalmology 1995;102:382-387.
11. Garcia DC, Woloj GM, Pineiro S, et al. An 8-year study of resistance to amikacin in gram-negative bacilli isolates from patients with nosocomial infection in one hospital in Argentina. J Med Microbiol 1995;42:283-290.
12. Sharma NS, Ooi JL, Downie JA, Coroneo MT. Corneal perforation and intraocular lens prolapse in Serratia marcescens endophthalmitis. Clin Exp Ophthalmol 2007;35:381-382.
13. Kunimoto DY, Tasman W, Rapuano C, et al. Endophthalmitis after penetrating keratoplasty: microbiologic spectrum and susceptibility of isolates. Am J Ophthalmol 2004;137:343-345.
14. Busbee BG, Recchia FM, Kaiser R, et al. Bleb-Associated endophthalmitis: clinical characteristics and visual outcomes. Ophthalmology 2004;111:1495-1503.
15. Wong JS, Chan TK, Lee HM, Chee SP. Endogenous bacterial bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction. Ophthalmology 2000;107: 1483-1491.
16. Pathengay A, Karosekar S, Raju B, et al. Microbiologic spectrum and susceptibility of isolates in scleral buckle infection in India. Am J Ophthalmol 2004;138:663-664.
17. Wilkowske CJ, Washington JA II, Martin WJ, et al. Biochemical characteristics, antibiotic susceptibility patterns, and clinical significance. JAMA 1970;214:157-162.
18. Lyerly D, Gray L, Kreger A. Characterization of rabbit corneal damage produced by Serratia keratitis and by a serratia protease. Infect Immun 1981;33:927-932.
19. De Courten C, Sancho P, BenEzra D. Metastatic Serratia marcescens endophthalmitis. J Pediatr Ophthalmol Strabismus 1988;25:45-47.
20. Chong Y, Lee K, Kwon OH. In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa, and other aerobic gram-negative bacilli. J Antimicrob Chemother 1993;32:21-29.